Pandemic Response Lab Launches Novel Triple-target Monkeypox Tests

Increased capacity, accuracy and accelerated turnaround time now makes monkeypox testing available at scale to curb the virus spread.


Long Island City, N.Y., Oct. 13, 2022 — Pandemic Response Lab (PRL), a wholly owned subsidiary of Opentrons Labworks, Inc., today announced two new three-target monkeypox tests, each developed and performed by its New York and Maryland laboratories, respectively. These skin lesion tests qualitatively detect three different viral genome targets of increasing spe

STIs in 3 Underserved Populations: How to Achieve Sexual Health Equity

Decades of research and practice have shown that individuals can be predisposed to certain medical conditions based on their demographic segment, leading to health disparities among socioeconomic groups. Negative outcomes within these groups are impacted by inequities in healthcare, such as the lack of proper nutrition, wellness education, clean water and others that can affect disease severity, access to testing and treatment, and more. A top priority for the CDC, as well as PRL, is to achieve

Customer Success Story - Kameo Health

A leader in innovative tech solutions, Kameo’s mission is to make it easy for productions to stay safe in the era of COVID-19. Kameo offers clients a suite of comprehensive tools through its testing management platform and provides efficient onsite testing services with fast results, leveraging over 300 nurses, a fleet of mobile labs and a network of 30 high-throughput PCR labs. Kameo has supported more than 375 productions and has administered over 300,000 COVID-19 tests for clients including N